Plasma‐derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community‐based study
Krell-Roesch, Janina
1; Zaniletti, Isabella; Syrjanen, Jeremy A.; Kremers, Walter K.; Algeciras-Schimnich, Alicia; Dage, Jeffrey L.; van Harten, Argonde C.; Fields, Julie A.; Knopman, David S.; Jack, Clifford R., Jr; Petersen, Ronald C.; Vassilaki, Maria; Geda, Yonas E.
1 Institut für Sport und Sportwissenschaft (IfSS), Karlsruher Institut für Technologie (KIT)
1; Zaniletti, Isabella; Syrjanen, Jeremy A.; Kremers, Walter K.; Algeciras-Schimnich, Alicia; Dage, Jeffrey L.; van Harten, Argonde C.; Fields, Julie A.; Knopman, David S.; Jack, Clifford R., Jr; Petersen, Ronald C.; Vassilaki, Maria; Geda, Yonas E.1 Institut für Sport und Sportwissenschaft (IfSS), Karlsruher Institut für Technologie (KIT)
Abstract:
INTRODUCTION: We examined associations between plasma-derived biomarkers of Alzheimer's disease (AD) and neuropsychiatric symptoms (NPS) in community-dwelling older adults.
METHODS: Cross-sectional study involving 1005 persons ≥50 years of age (mean 74 years, 564 male, 118 cognitively impaired), who completed plasma-derived biomarker (amyloid beta 42 [Aβ42]/Aβ40, phosphorylated tau 181 [p-tau181], p-tau217, total tau [t-tau], neurofilament light [NfL]), and NPS assessment.
RESULTS: P-tau181 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.41–3.00, p < 0.001), p-tau217 (OR 1.70, 95% CI 1.10–2.61, p = 0.016), and t-tau (OR 1.44, 95% CI 1.08–1.92, p = 0.012) were associated with appetite change. We also found that p-tau181 and p-tau217 were associated with increased symptoms of agitation (OR 1.93, 95% CI 1.20–3.11, p = 0.007 and OR 2.04, 95% CI 1.21–3.42, p = 0.007, respectively), and disinhibition (OR 2.39, 95% CI 1.45–3.93, p = 0.001 and OR 2.30, 95% CI 1.33–3.98, p = 0.003, respectively). Aβ42/Aβ40 and NfL were not associated with NPS.
CONCLUSION: Higher plasma-derived p-tau181 and p-tau217 levels are associated with increased symptoms of appetite change, agitation, and disinhibition. ... mehr
METHODS: Cross-sectional study involving 1005 persons ≥50 years of age (mean 74 years, 564 male, 118 cognitively impaired), who completed plasma-derived biomarker (amyloid beta 42 [Aβ42]/Aβ40, phosphorylated tau 181 [p-tau181], p-tau217, total tau [t-tau], neurofilament light [NfL]), and NPS assessment.
RESULTS: P-tau181 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.41–3.00, p < 0.001), p-tau217 (OR 1.70, 95% CI 1.10–2.61, p = 0.016), and t-tau (OR 1.44, 95% CI 1.08–1.92, p = 0.012) were associated with appetite change. We also found that p-tau181 and p-tau217 were associated with increased symptoms of agitation (OR 1.93, 95% CI 1.20–3.11, p = 0.007 and OR 2.04, 95% CI 1.21–3.42, p = 0.007, respectively), and disinhibition (OR 2.39, 95% CI 1.45–3.93, p = 0.001 and OR 2.30, 95% CI 1.33–3.98, p = 0.003, respectively). Aβ42/Aβ40 and NfL were not associated with NPS.
CONCLUSION: Higher plasma-derived p-tau181 and p-tau217 levels are associated with increased symptoms of appetite change, agitation, and disinhibition. ... mehr
| Zugehörige Institution(en) am KIT | Institut für Sport und Sportwissenschaft (IfSS) |
| Publikationstyp | Zeitschriftenaufsatz |
| Publikationsmonat/-jahr | 07.2023 |
| Sprache | Englisch |
| Identifikator | ISSN: 2352-8729 KITopen-ID: 1000161533 |
| Erschienen in | Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring |
| Verlag | Wiley Open Access |
| Band | 15 |
| Heft | 3 |
| Seiten | Art.-Nr.: e12461 |
| Vorab online veröffentlicht am | 30.07.2023 |
| Schlagwörter | Alzheimer's disease, neuropsychiatric symptoms, plasma biomarkers |
| Nachgewiesen in | Dimensions Scopus |